Despite advances in retinal imaging technology, patient disease activity can be missed in vision-threatening conditions. This oversight in everyday practice has the potential for undertreatment in patients. In addition, treatment delays further impact vision, worsening outcomes. Delays are in part due to a lack of awareness and urgency from the patient.
RetinAI’s Disease Evaluation Apps are accessed via Heidelberg AppWay. AppWay is a secure data transfer portal integrated in Heidelberg’s HEYEX 2.6. The Disease Apps provide expert-level analysis of a patient’s OCT volumes. Results are generated during the patient’s visit to complement evaluation and management of retinal diseases. The results can be used to better understand disease and status of biomarkers, and can provide valuable education and visualization of disease and biomarkers, empowering patients to be engaged in their disease management.
MEASURES TOTAL RETINAL AND LAYER THICKNESS FOR THE FOLLOWING LAYERS:
Retinal Nerve Fiber Layer (RNFL; Ganglion Cell Layer (GCL) + Inner Plexiform Layer (IPL); Inner Nuclear Layer (INL) + Outer Plexiform Layer (OPL); Outer Nuclear Layer (ONL); Photoreceptor (PR) + Retinal Pigment Epithelium (RPE; and Choriocapillaris (CC) + Choroidal Stroma (CS).
PROVIDES PROBABILITY OF PRESENCE/ABSENCE OF RETINAL BIOMARKERS AT A B-SCAN LEVEL IN OCT VOLUMES. THE BIOMARKERS IDENTIFIED ARE:
Fluids (SRF, IRF and Fibrous PED), Hyper reflective Foci (HF), Drusen, Reticular Pseudodrusen (RPD), Epiretinal Membrane (EPM), Geographic Atrophy (GA) and Outer Retinal Atrophy (ORA).
RetinAI Discovery® and the AI models are CE-Marked medical devices according to the Medical Devices Directive 93/42/EEC.
RetinAI Discovery® is a 510(k) FDA Cleared medical device in US.
RetinAI Discovery® and Retinai® are both trademarks of RetinAI Medical AG.
AI Models are CE-Marked medical devices since December 2020 & April 2021.